You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股业绩》安进药厂季绩胜预期 惟市後股价偏软
阿思达克 07-29 09:38
美国安进药厂(Amgen)(AMGN.US)公布第二季度业绩。季度纯利18.03亿美元,按年跌约17%。每股季度摊薄纯利3.05美元,经调整後为4.25美元,高於市场预期的3.84美元。季度收益62.06亿美元,按年升近6%,大致符合市场预期。

季度销售受新增牛皮癣药Otezla销售影响,抵销其他药物销售因疫情下跌的影响。Otezla季度销售5.61亿美元,高於市场预期的5.4亿美元。公司修定全年每股经调整纯利预测,由介乎10.65至11.45美元调整至介乎10.73至11.43美元,并维持全年收入介乎250亿至256亿美元的预测。

安进股价在延长交易时段跌1.5%,报251.5美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account